Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double-blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Prevention of Cutaneous Scarring in Skin Grafts and Donor Sites.

NCT04186273 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT04186273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double-blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Prevention of Cutaneous Scarring in Skin Grafts and Donor Sites.
Lead sponsor
University of British Columbia
Phase
Phase 2
Overall status
Unknown status
Start date
December 5, 2019
Completion date
March 1, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cicatrix, donor site complication, hypertrophic scar, keloid, scar, skin graft complications, skin graft scar